Cargando…
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with establi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604302/ https://www.ncbi.nlm.nih.gov/pubmed/34797832 http://dx.doi.org/10.1371/journal.pone.0259372 |
_version_ | 1784601928854929408 |
---|---|
author | Aoki, Yasunori Hamrén, Bengt Clegg, Lindsay E. Stahre, Christina Bhatt, Deepak L. Raz, Itamar Scirica, Benjamin M. Oscarsson, Jan Carlsson, Björn |
author_facet | Aoki, Yasunori Hamrén, Bengt Clegg, Lindsay E. Stahre, Christina Bhatt, Deepak L. Raz, Itamar Scirica, Benjamin M. Oscarsson, Jan Carlsson, Björn |
author_sort | Aoki, Yasunori |
collection | PubMed |
description | OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with established CV disease. Unsupervised machine learning technique called “k-means clustering” was used to divide patients into subtypes. K-means clustering including HbA1c, age of diagnosis, BMI, HOMA2-IR and HOMA2-B was used to assign clusters to the following diabetes subtypes: severe insulin deficient diabetes (SIDD); severe insulin-resistant diabetes (SIRD); mild obesity-related diabetes (MOD); mild age-related diabetes (MARD). We refer these subtypes as “clustering-based diabetes subtypes”. A simulation study using randomly generated data was conducted to understand how correlations between the above variables influence the formation of the cluster-based diabetes subtypes. The predictive utility of clustering-based diabetes subtypes for CV events (3-point MACE), renal function reduction (eGFR decrease >30%) and diabetic disease progression (introduction of additional anti-diabetic medication) were compared with conventional risk scores. Hazard ratios (HR) were estimated by Cox-proportional hazard models. RESULTS: In the SAVOR-TIMI 53 trial based dataset, the percentage of the clustering-based T2D subtypes were; SIDD (18%), SIRD (17%), MOD (29%), MARD (37%). Using the simulated dataset, the diabetes subtypes could be largely reproduced from a log-normal distribution when including known correlations between variables. The predictive utility of clustering-based diabetic subtypes on CV events, renal function reduction, and diabetic disease progression did not show an advantage compared to conventional risk scores. CONCLUSIONS: The consistent reproduction of four clustering-based T2D subtypes can be explained by the correlations between the variables used for clustering. Subtypes of T2D based on clustering had limited advantage compared to conventional risk scores to predict clinical outcome in patients with T2D and established CV disease. |
format | Online Article Text |
id | pubmed-8604302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86043022021-11-20 Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) Aoki, Yasunori Hamrén, Bengt Clegg, Lindsay E. Stahre, Christina Bhatt, Deepak L. Raz, Itamar Scirica, Benjamin M. Oscarsson, Jan Carlsson, Björn PLoS One Research Article OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with established CV disease. Unsupervised machine learning technique called “k-means clustering” was used to divide patients into subtypes. K-means clustering including HbA1c, age of diagnosis, BMI, HOMA2-IR and HOMA2-B was used to assign clusters to the following diabetes subtypes: severe insulin deficient diabetes (SIDD); severe insulin-resistant diabetes (SIRD); mild obesity-related diabetes (MOD); mild age-related diabetes (MARD). We refer these subtypes as “clustering-based diabetes subtypes”. A simulation study using randomly generated data was conducted to understand how correlations between the above variables influence the formation of the cluster-based diabetes subtypes. The predictive utility of clustering-based diabetes subtypes for CV events (3-point MACE), renal function reduction (eGFR decrease >30%) and diabetic disease progression (introduction of additional anti-diabetic medication) were compared with conventional risk scores. Hazard ratios (HR) were estimated by Cox-proportional hazard models. RESULTS: In the SAVOR-TIMI 53 trial based dataset, the percentage of the clustering-based T2D subtypes were; SIDD (18%), SIRD (17%), MOD (29%), MARD (37%). Using the simulated dataset, the diabetes subtypes could be largely reproduced from a log-normal distribution when including known correlations between variables. The predictive utility of clustering-based diabetic subtypes on CV events, renal function reduction, and diabetic disease progression did not show an advantage compared to conventional risk scores. CONCLUSIONS: The consistent reproduction of four clustering-based T2D subtypes can be explained by the correlations between the variables used for clustering. Subtypes of T2D based on clustering had limited advantage compared to conventional risk scores to predict clinical outcome in patients with T2D and established CV disease. Public Library of Science 2021-11-19 /pmc/articles/PMC8604302/ /pubmed/34797832 http://dx.doi.org/10.1371/journal.pone.0259372 Text en © 2021 Aoki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Aoki, Yasunori Hamrén, Bengt Clegg, Lindsay E. Stahre, Christina Bhatt, Deepak L. Raz, Itamar Scirica, Benjamin M. Oscarsson, Jan Carlsson, Björn Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title | Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title_full | Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title_fullStr | Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title_full_unstemmed | Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title_short | Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) |
title_sort | assessing reproducibility and utility of clustering of patients with type 2 diabetes and established cv disease (savor -timi 53 trial) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604302/ https://www.ncbi.nlm.nih.gov/pubmed/34797832 http://dx.doi.org/10.1371/journal.pone.0259372 |
work_keys_str_mv | AT aokiyasunori assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT hamrenbengt assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT clegglindsaye assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT stahrechristina assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT bhattdeepakl assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT razitamar assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT sciricabenjaminm assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT oscarssonjan assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial AT carlssonbjorn assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial |